280582950	280582950	CD	B-NP	O
|	|	NN	I-NP	O
DSH	DSH	NN	I-NP	O
|	|	NN	I-NP	O
59612947	59612947	CD	I-NP	O
|	|	NN	I-NP	O
|	|	NN	I-NP	O
1184109	1184109	CD	B-NP	O
|	|	CC	I-NP	O
2/28/2005	2/28/2005	CD	I-NP	O
12	12	CD	I-NP	O
:	:	:	O	O
00	00	CD	B-NP	O
:	:	:	O	O
00	00	CD	B-NP	O
AM	AM	VBP	B-VP	O
|	|	JJ	B-NP	B-protein
UNSTABLE	UNSTABLE	NNP	I-NP	I-protein
ANGINA	ANGINA	NNP	I-NP	I-protein
|	|	NNP	I-NP	I-protein
Signed	Signed	NNP	I-NP	I-protein
|	|	NNP	I-NP	I-protein
DIS	DIS	NNP	I-NP	I-protein
|	|	NNP	I-NP	I-protein
Admission	Admission	NNP	I-NP	O
Date	Date	NNP	I-NP	O
:	:	:	O	O
10/26/2005	10/26/2005	CD	B-NP	O
Report	Report	NNP	I-NP	O
Status	Status	NNP	I-NP	O
:	:	:	O	O
Signed	Signed	NNP	B-NP	O
Discharge	Discharge	NNP	I-NP	O
Date	Date	NNP	I-NP	O
:	:	:	O	O
11/24/2005	11/24/2005	CD	B-NP	O
ATTENDING	ATTENDING	NN	I-NP	O
:	:	:	O	O
FABROQUEZ	FABROQUEZ	NNP	B-NP	O
,	,	,	O	O
COY	COY	NNP	B-NP	O
MD	MD	NNP	I-NP	O
CHIEF	CHIEF	NNP	I-NP	O
COMPLAINT	COMPLAINT	NNP	I-NP	O
:	:	:	O	O
Cough	Cough	NNP	B-NP	O
,	,	,	O	O
nausea	nausea	NN	B-NP	O
,	,	,	O	O
vomiting	vomiting	NN	B-NP	O
,	,	,	O	O
and	and	CC	O	O
chest	chest	NN	B-NP	O
pain	pain	NN	I-NP	O
.	.	.	O	O

HISTORY	HISTORY	NN	B-NP	O
OF	OF	IN	B-PP	O
PRESENT	PRESENT	JJ	B-NP	O
ILLNESS	ILLNESS	NN	I-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
is	be	VBZ	B-VP	O
a	a	DT	B-NP	O
64-year-old	64-year-old	JJ	I-NP	O
female	female	NN	I-NP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
past	past	JJ	I-NP	O
medical	medical	JJ	I-NP	O
history	history	NN	I-NP	O
significant	significant	JJ	B-ADJP	O
for	for	IN	B-PP	O
coronary	coronary	JJ	B-NP	O
artery	artery	NN	I-NP	O
disease	disease	NN	I-NP	O
,	,	,	O	O
diabetes	diabetes	NN	B-NP	O
,	,	,	O	O
hypertension	hypertension	NN	B-NP	O
,	,	,	O	O
CHF	CHF	NN	B-NP	B-protein
,	,	,	O	O
and	and	CC	O	O
COPD	COPD	NN	B-NP	O
who	who	WP	B-NP	O
was	be	VBD	B-VP	O
admitted	admit	VBN	I-VP	O
on	on	IN	B-PP	O
2/21/05	2/21/05	CD	B-NP	O
after	after	IN	B-PP	O
presenting	present	VBG	B-VP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
emergency	emergency	NN	I-NP	O
department	department	NN	I-NP	O
complaining	complain	VBG	B-VP	O
of	of	IN	B-PP	O
three	three	CD	B-NP	O
weeks	week	NNS	I-NP	O
of	of	IN	B-PP	O
feeling	feeling	NN	B-NP	O
unwell	unwell	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
states	state	VBZ	B-VP	O
that	that	IN	B-SBAR	O
approximately	approximately	RB	B-NP	O
three	three	CD	I-NP	O
weeks	week	NNS	I-NP	O
prior	prior	RB	B-ADVP	O
to	to	TO	B-PP	O
admission	admission	NN	B-NP	O
,	,	,	O	O
she	she	PRP	B-NP	O
developed	develop	VBD	B-VP	O
increased	increase	VBN	I-VP	O
lower	low	JJR	B-NP	O
extremity	extremity	NN	I-NP	O
edema	edema	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
also	also	RB	B-ADVP	O
noted	note	VBD	B-VP	O
increased	increased	JJ	B-NP	O
cough	cough	NN	I-NP	O
and	and	CC	I-NP	O
shortness	shortness	NN	I-NP	O
of	of	IN	B-PP	O
breath	breath	NN	B-NP	O
.	.	.	O	O

Approximately	Approximately	RB	B-NP	O
two	two	CD	I-NP	O
weeks	week	NNS	I-NP	O
prior	prior	RB	B-ADVP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
admission	admission	NN	I-NP	O
,	,	,	O	O
she	she	PRP	B-NP	O
doubled	double	VBD	B-VP	O
her	her	PRP$	B-NP	O
Lasix	Lasix	NNP	I-NP	O
dose	dose	NN	I-NP	O
without	without	IN	B-PP	O
much	much	JJ	B-NP	O
improvement	improvement	NN	I-NP	O
in	in	IN	B-PP	O
her	her	PRP$	B-NP	O
symptoms	symptom	NNS	I-NP	O
.	.	.	O	O

About	About	RB	B-NP	O
one	one	CD	I-NP	O
week	week	NN	I-NP	O
prior	prior	JJ	B-ADJP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
admission	admission	NN	I-NP	O
,	,	,	O	O
she	she	PRP	B-NP	O
began	begin	VBD	B-VP	O
to	to	TO	I-VP	O
have	have	VB	I-VP	O
abdominal	abdominal	JJ	B-NP	O
pain	pain	NN	I-NP	O
,	,	,	O	O
nausea	nausea	NN	B-NP	O
,	,	,	O	O
and	and	CC	O	O
vomiting	vomiting	NN	B-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
continued	continue	VBD	B-VP	O
to	to	TO	I-VP	O
have	have	VB	I-VP	O
cough	cough	NN	B-NP	O
and	and	CC	I-NP	O
shortness	shortness	NN	I-NP	O
of	of	IN	B-PP	O
breath	breath	NN	B-NP	O
at	at	IN	B-PP	O
this	this	DT	B-NP	O
time	time	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
evening	evening	NN	I-NP	O
prior	prior	JJ	B-ADJP	O
to	to	TO	B-PP	O
presentation	presentation	NN	B-NP	O
,	,	,	O	O
she	she	PRP	B-NP	B-protein
had	have	VBD	B-VP	I-protein
substernal	substernal	JJ	B-NP	I-protein
chest	chest	NN	I-NP	I-protein
pain	pain	NN	I-NP	I-protein
,	,	,	O	O
which	which	WDT	B-NP	O
radiated	radiate	VBD	B-VP	O
to	to	TO	B-PP	O
her	her	PRP$	B-NP	O
arm	arm	NN	I-NP	O
x1	x1	NN	I-NP	O
hour	hour	NN	I-NP	O
.	.	.	O	O

This	This	DT	B-NP	O
pain	pain	NN	I-NP	O
improved	improve	VBD	B-VP	O
after	after	IN	B-PP	O
taking	take	VBG	B-VP	O
two	two	CD	B-NP	O
sublingual	sublingual	JJ	I-NP	O
nitroglycerin	nitroglycerin	NN	I-NP	O
tables	table	NNS	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
presented	present	VBD	B-VP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
emergency	emergency	NN	I-NP	O
department	department	NN	I-NP	O
the	the	DT	B-NP	O
following	follow	VBG	I-NP	O
day	day	NN	I-NP	O
complaining	complain	VBG	B-VP	O
of	of	IN	B-PP	O
shortness	shortness	NN	B-NP	O
of	of	IN	B-PP	O
breath	breath	NN	B-NP	O
and	and	CC	I-NP	O
fatigue	fatigue	NN	I-NP	O
.	.	.	O	O

In	In	IN	B-PP	O
the	the	DT	B-NP	O
emergency	emergency	NN	I-NP	O
department	department	NN	I-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
's	's	POS	B-NP	O
vital	vital	JJ	I-NP	O
signs	sign	NNS	I-NP	O
were	be	VBD	B-VP	O
noted	note	VBN	I-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
heart	heart	NN	B-NP	O
rate	rate	NN	I-NP	O
of	of	IN	B-PP	O
72	72	CD	B-NP	O
,	,	,	O	O
blood	blood	NN	B-NP	O
pressure	pressure	NN	I-NP	O
of	of	IN	B-PP	O
94/40	94/40	CD	B-NP	O
with	with	IN	B-PP	O
O2	O2	NN	B-NP	B-protein
sat	sit	VBD	B-VP	O
98	98	CD	B-NP	O
%	%	NN	I-NP	O
on	on	IN	B-PP	O
room	room	NN	B-NP	O
air	air	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
complaining	complain	VBG	I-VP	O
of	of	IN	B-PP	O
shortness	shortness	NN	B-NP	O
of	of	IN	B-PP	O
breath	breath	NN	B-NP	O
and	and	CC	I-NP	O
fatigue	fatigue	NN	I-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
blood	blood	NN	I-NP	O
pressure	pressure	NN	I-NP	O
subsequently	subsequently	RB	B-ADVP	O
decreased	decrease	VBD	B-VP	O
further	further	RB	B-ADVP	O
to	to	TO	B-PP	O
77/48	77/48	CD	B-NP	O
.	.	.	O	O

At	At	IN	B-PP	O
this	this	DT	B-NP	O
time	time	NN	I-NP	O
,	,	,	O	O
she	she	PRP	B-NP	O
was	be	VBD	B-VP	O
bolused	boluse	VBN	I-VP	O
with	with	IN	B-PP	O
IV	IV	CD	B-NP	O
fluids	fluid	NNS	I-NP	O
,	,	,	O	O
approximately	approximately	RB	B-NP	O
1.5	1.5	CD	I-NP	O
to	to	TO	I-NP	O
2	2	CD	I-NP	O
liters	liter	NNS	I-NP	O
.	.	.	O	O

Following	Follow	VBG	B-PP	O
the	the	DT	B-NP	O
fluid	fluid	NN	I-NP	O
bolus	bolus	NN	I-NP	O
,	,	,	O	O
she	she	PRP	B-NP	O
developed	develop	VBD	B-VP	O
wheezing	wheezing	NN	B-NP	O
and	and	CC	O	O
was	be	VBD	B-VP	O
treated	treat	VBN	I-VP	O
with	with	IN	B-PP	O
nebulizers	nebulizer	NNS	B-NP	O
.	.	.	O	O

However	However	RB	B-ADVP	O
,	,	,	O	O
she	she	PRP	B-NP	O
became	become	VBD	B-VP	O
more	more	RBR	B-ADJP	O
nauseated	nauseated	JJ	I-ADJP	O
and	and	CC	I-ADJP	O
dyspneic	dyspneic	JJ	I-ADJP	O
and	and	CC	O	O
her	her	PRP$	B-NP	O
blood	blood	NN	I-NP	O
pressure	pressure	NN	I-NP	O
continued	continue	VBD	B-VP	O
to	to	TO	I-VP	O
fall	fall	VB	I-VP	O
.	.	.	O	O

Dopamine	Dopamine	NN	B-NP	O
was	be	VBD	B-VP	O
started	start	VBN	I-VP	O
for	for	IN	B-PP	O
blood	blood	NN	B-NP	O
pressure	pressure	NN	I-NP	O
support	support	NN	I-NP	O
.	.	.	O	O

When	When	WRB	B-ADVP	O
she	she	PRP	B-NP	O
continued	continue	VBD	B-VP	O
to	to	TO	I-VP	O
desaturate	desaturate	VB	I-VP	O
into	into	IN	B-PP	O
the	the	DT	B-NP	O
80	80	CD	I-NP	O
%	%	NN	I-NP	O
range	range	NN	I-NP	O
and	and	CC	O	O
she	she	PRP	B-NP	O
was	be	VBD	B-VP	O
subsequently	subsequently	RB	I-VP	O
intubated	intubate	VBN	I-VP	O
.	.	.	O	O

An	An	DT	B-NP	O
echocardiogram	echocardiogram	NN	I-NP	O
at	at	IN	B-PP	O
the	the	DT	B-NP	O
bedtime	bedtime	NN	I-NP	O
showed	show	VBD	B-VP	O
a	a	DT	B-NP	O
globally	globally	RB	I-NP	O
depressed	depressed	JJ	I-NP	O
ejection	ejection	NN	I-NP	O
fraction	fraction	NN	I-NP	O
of	of	IN	B-PP	O
25	25	CD	B-NP	O
%	%	NN	I-NP	O
.	.	.	O	O

In	In	IN	B-PP	O
addition	addition	NN	B-NP	O
,	,	,	O	O
her	her	PRP$	B-NP	O
labs	lab	NNS	I-NP	O
returned	return	VBD	B-VP	O
with	with	IN	B-PP	O
an	an	DT	B-NP	O
elevated	elevated	JJ	I-NP	O
troponin	troponin	NN	I-NP	O
of	of	IN	B-PP	O
4.5	4.5	CD	B-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
had	have	VBD	B-VP	O
a	a	DT	B-NP	O
subsequent	subsequent	JJ	I-NP	O
chest	chest	NN	I-NP	O
x-ray	x-ray	NN	I-NP	O
,	,	,	O	O
which	which	WDT	B-NP	O
documented	document	VBD	B-VP	O
pulmonary	pulmonary	JJ	B-NP	O
edema	edema	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
admitted	admit	VBN	I-VP	O
for	for	IN	B-PP	O
flash	flash	NN	B-NP	O
pulmonary	pulmonary	JJ	I-NP	O
edema	edema	NN	I-NP	O
and	and	CC	O	O
was	be	VBD	B-VP	O
transferred	transfer	VBN	I-VP	O
directly	directly	RB	B-ADVP	O
from	from	IN	B-PP	O
the	the	DT	B-NP	O
emergency	emergency	NN	I-NP	O
department	department	NN	I-NP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
cardiac	cardiac	JJ	I-NP	O
cath	cath	NN	I-NP	O
laboratory	laboratory	NN	I-NP	O
.	.	.	O	O

In	In	IN	B-PP	O
the	the	DT	B-NP	O
cath	cath	NN	I-NP	O
lab	lab	NN	I-NP	O
,	,	,	O	O
her	her	PRP$	B-NP	O
bypass	bypass	NN	I-NP	O
grafts	graft	NNS	I-NP	O
of	of	IN	B-PP	O
the	the	DT	B-NP	O
LIMA	LIMA	NN	I-NP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
LAD	LAD	NN	I-NP	O
and	and	CC	I-NP	O
SVG	SVG	NN	I-NP	O
to	to	TO	B-PP	O
OMB	OMB	NN	B-NP	B-protein
were	be	VBD	B-VP	O
noted	note	VBN	I-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
patent	patent	NN	B-NP	O
.	.	.	O	O

However	However	RB	B-ADVP	O
,	,	,	O	O
all	all	PDT	B-NP	O
the	the	DT	I-NP	O
other	other	JJ	I-NP	O
grafts	graft	NNS	I-NP	O
were	be	VBD	B-VP	O
occluded	occlude	VBN	I-VP	O
.	.	.	O	O

No	No	DT	B-NP	O
interventions	intervention	NNS	I-NP	O
were	be	VBD	B-VP	O
undertaken	undertake	VBN	I-VP	O
.	.	.	O	O

She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
also	also	RB	I-VP	O
noted	note	VBN	I-VP	O
to	to	TO	I-VP	O
have	have	VB	I-VP	O
elevated	elevate	VBN	I-VP	O
right	right	JJ	B-NP	O
and	and	CC	I-NP	O
left-sided	left-sided	JJ	I-NP	O
pressures	pressure	NNS	I-NP	O
with	with	IN	B-PP	O
right	right	JJ	B-NP	O
atrial	atrial	JJ	I-NP	O
pressure	pressure	NN	I-NP	O
of	of	IN	B-PP	O
32	32	CD	B-NP	O
and	and	CC	O	O
a	a	DT	B-NP	O
mean	mean	JJ	I-NP	O
pulmonary	pulmonary	JJ	I-NP	O
artery	artery	NN	I-NP	O
pressure	pressure	NN	I-NP	O
of	of	IN	B-PP	O
51	51	CD	B-NP	O
and	and	CC	O	O
a	a	DT	B-NP	O
left	left	JJ	I-NP	O
wedge	wedge	NN	I-NP	O
pressure	pressure	NN	I-NP	O
of	of	IN	B-PP	O
40	40	CD	B-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
subsequently	subsequently	RB	I-VP	O
transferred	transfer	VBN	I-VP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
CCU	CCU	NN	I-NP	B-DNA
where	where	WRB	B-ADVP	I-DNA
she	she	PRP	B-NP	O
was	be	VBD	B-VP	O
also	also	RB	I-VP	O
noted	note	VBN	I-VP	O
to	to	TO	I-VP	O
have	have	VB	I-VP	O
a	a	DT	B-NP	O
serum	serum	NN	I-NP	O
creatinine	creatinine	NN	I-NP	O
of	of	IN	B-PP	O
2.3	2.3	CD	B-NP	O
and	and	CC	O	O
making	make	VBG	B-VP	O
very	very	RB	B-NP	O
small	small	JJ	I-NP	O
amounts	amount	NNS	I-NP	O
of	of	IN	B-PP	O
urine	urine	NN	B-NP	O
.	.	.	O	O

A	A	DT	B-NP	O
pH	pH	NN	I-NP	O
at	at	IN	B-PP	O
that	that	DT	B-NP	O
time	time	NN	I-NP	O
was	be	VBD	B-VP	O
7.13	7.13	CD	B-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
cardiac	cardiac	JJ	I-NP	O
output	output	NN	I-NP	O
,	,	,	O	O
cardiac	cardiac	JJ	B-NP	O
index	index	NN	I-NP	O
ratios	ratio	NNS	I-NP	O
were	be	VBD	B-VP	O
6.8	6.8	CD	B-NP	O
to	to	TO	B-PP	O
3	3	CD	B-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
treated	treat	VBN	I-VP	O
with	with	IN	B-PP	O
sodium	sodium	NN	B-NP	O
bicarb	bicarb	NN	I-NP	O
and	and	CC	O	O
Lasix	Lasix	NN	B-NP	O
IV	IV	CD	I-NP	O
drip	drip	NN	I-NP	O
.	.	.	O	O

Overnight	Overnight	RB	B-ADVP	O
,	,	,	O	O
she	she	PRP	B-NP	O
developed	develop	VBD	B-VP	O
a	a	DT	B-NP	O
brisk	brisk	JJ	I-NP	O
diuresis	diuresis	NN	I-NP	O
and	and	CC	O	O
her	her	PRP$	B-NP	O
hypotension	hypotension	NN	I-NP	O
resolved	resolve	VBN	B-VP	O
.	.	.	O	O

An	An	DT	B-NP	O
echocardiogram	echocardiogram	NN	I-NP	O
obtained	obtain	VBN	B-VP	O
on	on	IN	B-PP	O
hospital	hospital	NN	B-NP	O
day	day	NN	I-NP	O
two	two	CD	B-NP	O
showed	show	VBD	B-VP	O
an	an	DT	B-NP	O
estimated	estimate	VBN	I-NP	O
ejection	ejection	NN	I-NP	O
fraction	fraction	NN	I-NP	O
of	of	IN	B-PP	O
45	45	CD	B-NP	O
%	%	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
entire	entire	JJ	I-NP	O
inferior	inferior	JJ	I-NP	O
wall	wall	NN	I-NP	O
was	be	VBD	B-VP	O
noted	note	VBN	I-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
akinetic	akinetic	JJ	B-ADJP	O
.	.	.	O	O

The	The	DT	B-NP	O
posterior	posterior	JJ	I-NP	O
wall	wall	NN	I-NP	O
was	be	VBD	B-VP	O
moderately	moderately	RB	B-ADJP	O
hypokinetic	hypokinetic	JJ	I-ADJP	O
.	.	.	O	O

Global	Global	JJ	B-NP	O
right	right	JJ	I-NP	O
ventricular	ventricular	JJ	I-NP	O
systolic	systolic	JJ	I-NP	O
function	function	NN	I-NP	O
was	be	VBD	B-VP	O
severely	severely	RB	I-VP	O
reduced	reduce	VBN	I-VP	O
.	.	.	O	O

She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
also	also	RB	B-ADVP	O
note	note	NN	B-NP	O
to	to	TO	B-VP	O
have	have	VB	I-VP	O
a	a	DT	B-NP	O
thickened	thicken	VBN	I-NP	O
,	,	,	I-NP	O
calcified	calcify	VBN	I-NP	O
mitral	mitral	JJ	I-NP	O
valve	valve	NN	I-NP	O
with	with	IN	B-PP	O
severe	severe	JJ	B-NP	O
mitral	mitral	JJ	I-NP	O
regurgitation	regurgitation	NN	I-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
CCU	CCU	NN	I-NP	O
course	course	NN	I-NP	O
was	be	VBD	B-VP	O
notable	notable	JJ	B-ADJP	O
for	for	IN	B-PP	O
two	two	CD	B-NP	O
positive	positive	JJ	I-NP	O
blood	blood	NN	I-NP	O
cultures	culture	NNS	I-NP	O
,	,	,	O	O
one	one	CD	B-NP	O
drawn	draw	VBN	B-VP	O
on	on	IN	B-PP	O
2/21/05	2/21/05	CD	B-NP	O
and	and	CC	O	O
the	the	DT	B-NP	O
other	other	JJ	I-NP	O
drawn	drawn	NN	I-NP	O
on	on	IN	B-PP	O
4/10/05	4/10/05	CD	B-NP	O
for	for	IN	B-PP	O
which	which	WDT	B-NP	O
she	she	PRP	B-NP	O
was	be	VBD	B-VP	O
started	start	VBN	I-VP	O
first	first	RB	B-ADVP	O
on	on	IN	B-PP	O
vancomycin	vancomycin	NN	B-NP	O
and	and	CC	O	O
then	then	RB	B-VP	O
switched	switch	VBN	I-VP	O
to	to	TO	B-PP	O
nafcillin	nafcillin	NN	B-NP	O
for	for	IN	B-PP	O
Coag-negative	Coag-negative	JJ	B-NP	O
staph	staph	NN	I-NP	O
bacteremia	bacteremia	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
also	also	RB	I-VP	O
diagnosed	diagnose	VBN	I-VP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
UTI	UTI	NN	I-NP	B-DNA
and	and	CC	O	O
started	start	VBN	B-VP	O
on	on	IN	B-PP	O
levofloxacin	levofloxacin	NN	B-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
eventually	eventually	RB	I-VP	O
extubated	extubate	VBN	I-VP	O
on	on	IN	B-PP	O
11/18/05	11/18/05	CD	B-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
discharged	discharge	VBN	I-VP	O
from	from	IN	B-PP	O
the	the	DT	B-NP	O
CCU	CCU	NN	I-NP	B-DNA
on	on	IN	B-PP	O
10/30/05	10/30/05	CD	B-NP	O
,	,	,	O	O
and	and	CC	O	O
was	be	VBD	B-VP	O
accepted	accept	VBN	I-VP	O
on	on	IN	B-PP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
Cards	Cards	NNP	I-NP	O
Aworth	Aworth	NNP	I-NP	O
Service	Service	NNP	I-NP	O
.	.	.	O	O

PAST	PAST	NNP	B-NP	O
MEDICAL	MEDICAL	NNP	I-NP	O
HISTORY	HISTORY	NNP	I-NP	O
:	:	:	O	O
1	1	CD	B-NP	O
.	.	.	O	O

Hypertension	Hypertension	NN	B-NP	O
.	.	.	O	O

2	2	LS	B-LST	O
.	.	.	O	O

Hypercholesterolemia	Hypercholesterolemia	NN	B-NP	O
.	.	.	O	O

3	3	LS	B-LST	O
.	.	.	O	O

Diabetes	Diabetes	NN	B-NP	O
mellitus	mellitus	NN	I-NP	O
.	.	.	O	O

4	4	LS	B-LST	O
.	.	.	O	O

Coronary	Coronary	JJ	B-NP	O
artery	artery	NN	I-NP	O
disease	disease	NN	I-NP	O
,	,	,	O	O
status	status	NN	B-NP	O
post	post	NN	I-NP	O
CABG	CABG	NN	I-NP	O
in	in	IN	B-PP	O
1995	1995	CD	B-NP	O
with	with	IN	B-PP	O
grafts	graft	NNS	B-NP	O
from	from	IN	B-PP	O
the	the	DT	B-NP	O
LIMA	LIMA	NN	I-NP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
LAD	LAD	NN	I-NP	O
,	,	,	O	O
SVG	SVG	NN	B-NP	O
to	to	TO	B-PP	O
RCA	RCA	NN	B-NP	B-protein
,	,	,	O	O
SVG	SVG	NN	B-NP	O
to	to	TO	B-PP	O
OM1	OM1	NN	B-NP	B-protein
,	,	,	O	O
SVG	SVG	NN	B-NP	O
to	to	TO	B-PP	O
OM2	OM2	NN	B-NP	B-protein
,	,	,	O	O
and	and	CC	O	O
RIMA	RIMA	NN	B-NP	B-protein
to	to	TO	B-PP	O
the	the	DT	B-NP	O
PDA	PDA	NN	I-NP	B-protein
.	.	.	O	O

5	5	LS	B-LST	O
.	.	.	O	O

Paroxysmal	Paroxysmal	JJ	B-NP	O
A-Fib	A-Fib	NN	I-NP	O
,	,	,	O	O
on	on	IN	B-PP	O
Coumadin	Coumadin	NN	B-NP	O
.	.	.	O	O

6	6	CD	B-NP	O
.	.	.	O	O

COPD	COPD	NN	B-NP	O
.	.	.	O	O

7	7	CD	B-NP	O
.	.	.	O	O

Non-Q	Non-Q	JJ	B-NP	O
wave	wave	NN	I-NP	O
MI	MI	NN	I-NP	O
in	in	IN	B-PP	O
2002	2002	CD	B-NP	O
.	.	.	O	O

8	8	CD	B-NP	O
.	.	.	O	O

Status	Status	NNP	B-NP	O
post	post	VBD	B-VP	O
right	right	JJ	B-NP	O
subtotal	subtotal	JJ	I-NP	O
repair	repair	NN	I-NP	O
parotidectomy	parotidectomy	NN	I-NP	O
.	.	.	O	O

9	9	CD	B-NP	O
.	.	.	O	O

Status	Status	NNP	B-NP	O
post	post	VBD	B-VP	O
tubal	tubal	JJ	B-NP	O
ligation	ligation	NN	I-NP	O
.	.	.	O	O

10	10	CD	B-NP	O
.	.	.	O	O

Breast	Breast	NN	B-NP	O
cancer	cancer	NN	I-NP	O
,	,	,	O	O
status	status	NN	B-NP	O
post	post	NN	I-NP	O
right	right	JJ	I-NP	O
modified	modify	VBN	I-NP	O
radical	radical	JJ	I-NP	O
mastectomy	mastectomy	NN	I-NP	O
.	.	.	O	O

11	11	CD	B-NP	O
.	.	.	O	O

History	History	NN	B-NP	O
of	of	IN	B-PP	O
CHF	CHF	NN	B-NP	B-protein
.	.	.	O	O

12	12	CD	B-NP	O
.	.	.	O	O

Chronic	Chronic	JJ	B-NP	O
guaiac-positive	guaiac-positive	JJ	I-NP	O
stool	stool	NN	I-NP	O
.	.	.	O	O

ALLERGIES	ALLERGIES	NNS	B-NP	O
:	:	:	O	O
No	No	DT	B-NP	O
known	know	VBN	I-NP	O
drug	drug	NN	I-NP	O
allergies	allergy	NNS	I-NP	O
.	.	.	O	O

HOME	HOME	NN	B-NP	O
MEDICATIONS	MEDICATIONS	NNS	I-NP	O
:	:	:	O	O
1	1	LS	B-LST	O
.	.	.	O	O

Aspirin	Aspirin	NN	B-NP	O
81	81	CD	I-NP	O
mg	mg	NN	I-NP	O
a	a	DT	B-NP	O
day	day	NN	I-NP	O
.	.	.	O	O

2	2	LS	B-LST	O
.	.	.	O	O

Atenolol	Atenolol	NN	B-NP	O
12.5	12.5	CD	I-NP	O
mg	mg	NN	I-NP	O
a	a	DT	B-NP	O
day	day	NN	I-NP	O
.	.	.	O	O

3	3	LS	B-LST	O
.	.	.	O	O

Wellbutrin	Wellbutrin	NN	B-NP	O
100	100	CD	I-NP	O
mg	mg	NN	I-NP	O
twice	twice	RB	B-NP	O
a	a	DT	I-NP	O
day	day	NN	I-NP	O
.	.	.	O	O

4	4	LS	B-LST	O
.	.	.	O	O

Zoloft	Zoloft	NNP	B-NP	O
225	225	CD	I-NP	O
mg	mg	NN	I-NP	O
once	once	RB	B-ADVP	O
a	a	DT	B-NP	O
day	day	NN	I-NP	O
.	.	.	O	O

5	5	LS	B-LST	O
.	.	.	O	O

Imdur	Imdur	IN	B-PP	O
30	30	CD	B-NP	O
mg	mg	NN	I-NP	O
a	a	DT	B-NP	O
day	day	NN	I-NP	O
.	.	.	O	O

6	6	CD	B-NP	O
.	.	.	O	O

Lisinopril	Lisinopril	NNP	B-NP	O
10	10	CD	I-NP	O
mg	mg	NN	I-NP	O
a	a	DT	B-NP	O
day	day	NN	I-NP	O
.	.	.	O	O

7	7	CD	B-NP	O
.	.	.	O	O

Nitroglycerin	Nitroglycerin	NN	B-NP	B-protein
p.r.n.	p.r.n.	NN	I-NP	I-protein
8	8	CD	I-NP	I-protein
.	.	.	O	O

Serevent	Serevent	NNP	B-NP	O
.	.	.	O	O

9	9	CD	B-NP	O
.	.	.	O	O

Flovent	Flovent	NN	B-NP	O
44	44	CD	I-NP	O
mcg	mcg	NN	I-NP	O
b.i.d.	b.i.d.	NN	I-NP	O
10	10	CD	I-NP	O
.	.	.	O	O

Diltiazem	Diltiazem	NN	B-NP	O
ER	ER	NN	I-NP	O
300	300	CD	I-NP	O
mg	mg	NN	I-NP	O
a	a	DT	B-NP	O
day	day	NN	I-NP	O
.	.	.	O	O

11	11	CD	B-NP	O
.	.	.	O	O

Pravastatin	Pravastatin	NN	B-NP	O
40	40	CD	I-NP	O
mg	mg	NN	I-NP	O
a	a	DT	B-NP	O
day	day	NN	I-NP	O
.	.	.	O	O

12	12	CD	B-NP	O
.	.	.	O	O

Coumadin	Coumadin	NN	B-NP	O
2.5	2.5	CD	I-NP	O
mg	mg	NN	I-NP	O
b.i.d.	b.i.d.	RB	B-NP	O
13	13	CD	I-NP	O
.	.	.	O	O

Senna	Senna	NNP	B-NP	O
.	.	.	O	O

14	14	CD	B-NP	O
.	.	.	O	O

Colace	Colace	NNP	B-NP	O
.	.	.	O	O

15	15	CD	B-NP	O
.	.	.	O	O

Iron	Iron	NN	B-NP	O
sulfate	sulfate	NN	I-NP	O
300	300	CD	I-NP	O
mg	mg	NN	I-NP	O
three	three	CD	B-NP	O
times	time	NNS	I-NP	O
a	a	DT	B-NP	O
day	day	NN	I-NP	O
.	.	.	O	O

16	16	CD	B-NP	O
.	.	.	O	O

K-Dur	K-Dur	NN	B-NP	O
20	20	CD	I-NP	O
mEq	mEq	NN	I-NP	O
.	.	.	O	O

a	a	DT	B-NP	O
day	day	NN	I-NP	O
.	.	.	O	O

17	17	CD	B-NP	O
.	.	.	O	O

Metformin	Metformin	NN	B-NP	O
1	1	CD	I-NP	O
gm	gm	NN	I-NP	O
twice	twice	RB	B-NP	O
a	a	DT	I-NP	O
day	day	NN	I-NP	O
.	.	.	O	O

18	18	CD	B-NP	O
.	.	.	O	O

Lantus	Lantus	NNP	B-NP	O
20	20	CD	I-NP	O
mg	mg	NN	I-NP	O
subcu	subcu	NN	I-NP	O
q.h.s.	q.h.s.	NN	I-NP	O
19	19	CD	I-NP	O
.	.	.	O	O

Percocet	Percocet	NNP	B-NP	O
.	.	.	O	O

20	20	CD	B-NP	O
.	.	.	O	O

Albuterol	Albuterol	NN	B-NP	O
p.r.n.	p.r.n.	NN	I-NP	O
21	21	CD	I-NP	O
.	.	.	O	O

Folate	Folate	NN	B-NP	O
.	.	.	O	O

22	22	CD	B-NP	O
.	.	.	O	O

Magnesium	Magnesium	NN	B-NP	O
gluconate	gluconate	NN	I-NP	O
1	1	CD	I-NP	O
gm	gm	NN	I-NP	O
three	three	CD	B-NP	O
times	time	NNS	I-NP	O
a	a	DT	B-NP	O
day	day	NN	I-NP	O
.	.	.	O	O

23	23	CD	B-NP	O
.	.	.	O	O

Loratadine	Loratadine	NN	B-NP	O
10	10	CD	I-NP	O
mg	mg	NN	I-NP	O
once	once	RB	B-ADVP	O
a	a	DT	B-NP	O
day	day	NN	I-NP	O
.	.	.	O	O

SOCIAL	SOCIAL	JJ	B-NP	O
HISTORY	HISTORY	NN	I-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
is	be	VBZ	B-VP	O
separated	separate	VBN	I-VP	O
from	from	IN	B-PP	O
her	her	PRP$	B-NP	O
husband	husband	NN	I-NP	O
,	,	,	O	O
and	and	CC	O	O
she	she	PRP	B-NP	O
has	have	VBZ	B-VP	O
several	several	JJ	B-NP	O
children	child	NNS	I-NP	O
who	who	WP	B-NP	O
live	live	VBP	B-VP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
same	same	JJ	I-NP	O
area	area	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
lives	live	VBZ	B-VP	O
with	with	IN	B-PP	O
her	her	PRP$	B-NP	O
son	son	NN	I-NP	O
and	and	CC	I-NP	O
grandson	grandson	NN	I-NP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
same	same	JJ	I-NP	O
house	house	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
is	be	VBZ	B-VP	O
a	a	DT	B-NP	O
current	current	JJ	I-NP	O
smoker	smoker	NN	I-NP	O
,	,	,	O	O
approximately	approximately	RB	B-NP	O
one-third	one-third	JJ	I-NP	O
pack	pack	NN	I-NP	O
per	per	IN	B-PP	O
day	day	NN	B-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
denies	deny	VBZ	B-VP	O
alcohol	alcohol	NN	B-NP	O
and	and	CC	I-NP	O
IV	IV	CD	I-NP	O
drug	drug	NN	I-NP	O
use	use	NN	I-NP	O
.	.	.	O	O

FAMILY	FAMILY	NN	B-NP	O
HISTORY	HISTORY	NN	I-NP	O
:	:	:	O	O
Notable	Notable	JJ	B-ADJP	O
for	for	IN	B-PP	O
a	a	DT	B-NP	O
sone	sone	NN	I-NP	O
with	with	IN	B-PP	O
schizophrenia	schizophrenia	NN	B-NP	O
.	.	.	O	O

LABORATORY	LABORATORY	NN	B-NP	O
STUDIES	STUDIES	VBZ	B-VP	O
ON	ON	NN	B-NP	O
ADMISSION	ADMISSION	NN	I-NP	O
:	:	:	O	O
CBC	CBC	NN	B-NP	B-protein
showed	show	VBD	B-VP	O
a	a	DT	B-NP	O
white	white	JJ	I-NP	O
blood	blood	NN	I-NP	O
cell	cell	NN	I-NP	O
count	count	NN	I-NP	O
of	of	IN	B-PP	O
6.07	6.07	CD	B-NP	O
,	,	,	O	O
hematocrit	hematocrit	NN	B-NP	B-protein
28.5	28.5	CD	I-NP	I-protein
,	,	,	O	O
and	and	CC	O	O
platelets	platelet	NNS	B-NP	B-cell_type
274	274	CD	I-NP	O
,	,	,	I-NP	O
000	000	CD	I-NP	O
.	.	.	O	O

INR	INR	NN	B-NP	O
2.3	2.3	CD	I-NP	O
.	.	.	O	O

PTT	PTT	NN	B-NP	B-protein
42.8	42.8	CD	I-NP	I-protein
and	and	CC	O	O
PT	PT	NN	B-NP	B-protein
25.8	25.8	CD	I-NP	I-protein
.	.	.	O	O

Sodium	Sodium	NN	B-NP	B-protein
131	131	NN	I-NP	I-protein
,	,	,	O	O
potassium	potassium	NN	B-NP	O
4.1	4.1	CD	I-NP	O
,	,	,	O	O
chloride	chloride	NN	B-NP	O
87	87	CD	I-NP	O
,	,	,	O	O
bicarb	bicarb	NN	B-NP	O
24	24	CD	I-NP	O
,	,	,	O	O
BUN	BUN	NN	B-NP	B-DNA
30	30	CD	I-NP	I-DNA
,	,	,	O	O
INR	INR	NN	B-NP	B-protein
2.3	2.3	CD	I-NP	I-protein
,	,	,	O	O
and	and	CC	O	O
glucose	glucose	NN	B-NP	B-protein
173	173	CD	I-NP	I-protein
.	.	.	O	O

ALT	ALT	NN	B-NP	B-protein
?	?	.	O	I-protein
?	?	.	O	I-protein
___	___	''	O	I-protein
?	?	.	O	O
?	?	.	O	O
,	,	,	O	O
AST	AST	NNP	B-NP	O
27	27	CD	I-NP	O
,	,	,	O	O
alkaline	alkaline	NN	B-NP	O
phosphatase	phosphatase	NN	I-NP	O
66	66	CD	I-NP	O
,	,	,	O	O
and	and	CC	O	O
total	total	JJ	B-NP	O
bili	bili	NN	I-NP	O
0.2	0.2	CD	I-NP	O
.	.	.	O	O

CK	CK	NN	B-NP	B-protein
141	141	CD	I-NP	I-protein
,	,	,	O	O
MB	MB	NN	B-NP	B-protein
8.2	8.2	CD	I-NP	I-protein
,	,	,	O	O
troponin	troponin	NN	B-NP	O
peaked	peak	VBD	B-VP	O
at	at	IN	B-PP	O
4.46	4.46	CD	B-NP	O
and	and	CC	O	O
subsequently	subsequently	RB	B-VP	O
trended	trend	VBN	I-VP	O
down	down	IN	B-PRT	O
.	.	.	O	O

HOSPITAL	HOSPITAL	JJ	B-NP	O
COURSE	COURSE	NN	I-NP	O
:	:	:	O	O
Following	Follow	VBG	B-VP	O
discharge	discharge	NN	B-NP	O
from	from	IN	B-PP	O
the	the	DT	B-NP	O
Coronary	Coronary	NNP	I-NP	O
Care	Care	NNP	I-NP	O
Unit	Unit	NNP	I-NP	O
:	:	:	O	O
In	In	IN	B-PP	O
summary	summary	NN	B-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
is	be	VBZ	B-VP	O
a	a	DT	B-NP	O
64-year-old	64-year-old	JJ	I-NP	O
female	female	NN	I-NP	O
,	,	,	O	O
admitted	admit	VBN	B-VP	O
on	on	IN	B-PP	O
2/21/05	2/21/05	CD	B-NP	O
,	,	,	O	O
complaining	complain	VBG	B-VP	O
of	of	IN	B-PP	O
subacute	subacute	JJ	B-NP	O
progressive	progressive	JJ	I-NP	O
symptoms	symptom	NNS	I-NP	O
of	of	IN	B-PP	O
CHF	CHF	NN	B-NP	B-protein
in	in	IN	B-PP	O
addition	addition	NN	B-NP	O
to	to	TO	B-PP	O
a	a	DT	B-NP	O
more	more	RBR	I-NP	O
acute	acute	JJ	I-NP	O
onset	onset	NN	I-NP	O
of	of	IN	B-PP	O
nausea	nausea	NN	B-NP	O
and	and	CC	I-NP	O
vomiting	vomiting	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
presented	present	VBD	B-VP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
emergency	emergency	NN	I-NP	O
department	department	NN	I-NP	O
hypotensive	hypotensive	NN	I-NP	O
,	,	,	O	O
which	which	WDT	B-NP	O
was	be	VBD	B-VP	O
probably	probably	RB	I-VP	O
related	relate	VBN	I-VP	O
to	to	TO	B-PP	O
dehydration	dehydration	NN	B-NP	O
due	due	JJ	B-ADJP	O
to	to	TO	B-PP	O
decreased	decrease	VBN	B-NP	O
p.o.	p.o.	NN	I-NP	O
intake	intake	NN	I-NP	O
as	as	RB	B-CONJP	O
well	well	RB	I-CONJP	O
as	as	IN	I-CONJP	O
continued	continued	JJ	B-NP	O
Lasix	Lasix	NNP	I-NP	O
use	use	NN	I-NP	O
.	.	.	O	O

When	When	WRB	B-ADVP	O
given	give	VBN	B-PP	O
IV	IV	CD	B-NP	O
fluids	fluid	NNS	I-NP	O
,	,	,	O	O
she	she	PRP	B-NP	O
went	go	VBD	B-VP	O
into	into	IN	B-PP	O
flash	flash	NN	B-NP	O
pulmonary	pulmonary	JJ	I-NP	O
edema	edema	NN	I-NP	O
,	,	,	O	O
requiring	require	VBG	B-VP	O
transfer	transfer	NN	B-NP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
CCU	CCU	NN	I-NP	B-DNA
and	and	CC	I-NP	O
intubation	intubation	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
underwent	undergo	VBD	B-VP	O
emergent	emergent	JJ	B-NP	O
cath	cath	NN	I-NP	O
,	,	,	O	O
which	which	WDT	B-NP	O
showed	show	VBD	B-VP	O
no	no	DT	B-NP	O
new	new	JJ	I-NP	O
intervenable	intervenable	JJ	I-NP	O
disease	disease	NN	I-NP	O
,	,	,	O	O
but	but	CC	O	O
did	do	VBD	B-VP	O
show	show	VB	I-VP	O
severe	severe	JJ	B-NP	O
MR.	MR.	NNP	I-NP	O
She	She	NNP	I-NP	O
was	be	VBD	B-VP	O
admitted	admit	VBN	I-VP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
CCU	CCU	NN	I-NP	B-DNA
where	where	WRB	B-ADVP	I-DNA
she	she	PRP	B-NP	O
was	be	VBD	B-VP	O
aggressively	aggressively	RB	I-VP	O
diuresed	diurese	VBN	I-VP	O
and	and	CC	O	O
weaned	wean	VBN	B-VP	O
of	of	IN	B-PP	O
the	the	DT	B-NP	O
vent	vent	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
transferred	transfer	VBN	I-VP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
floor	floor	NN	I-NP	O
on	on	IN	B-PP	O
4/13/05	4/13/05	CD	B-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
hospital	hospital	NN	I-NP	O
course	course	NN	I-NP	O
by	by	IN	B-PP	O
system	system	NN	B-NP	O
is	be	VBZ	B-VP	O
as	as	IN	B-SBAR	O
follows	follow	VBZ	B-VP	O
.	.	.	O	O

Cardiac	Cardiac	JJ	B-NP	O
ischemia	ischemia	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
underwent	undergo	VBD	B-VP	O
catheterization	catheterization	NN	B-NP	O
on	on	IN	B-PP	O
2/21/05	2/21/05	CD	B-NP	O
,	,	,	O	O
which	which	WDT	B-NP	O
showed	show	VBD	B-VP	O
100	100	CD	B-NP	O
%	%	NN	I-NP	O
obstruction	obstruction	NN	I-NP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
SVG	SVG	NN	I-NP	O
to	to	TO	B-PP	O
RCA	RCA	NN	B-NP	O
graft	graft	NN	I-NP	O
,	,	,	O	O
60	60	CD	B-NP	O
%	%	NN	I-NP	O
obstruction	obstruction	NN	I-NP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
RIMA	RIMA	NN	I-NP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
marginal	marginal	JJ	I-NP	O
1	1	CD	I-NP	O
graft	graft	NN	I-NP	O
,	,	,	O	O
patent	patent	NN	B-NP	O
LIMA	LIMA	NN	I-NP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
LAD	LAD	NN	I-NP	O
,	,	,	O	O
and	and	CC	O	O
patent	patent	NN	B-NP	O
SVG	SVG	NN	I-NP	O
to	to	TO	B-PP	O
OM1	OM1	NN	B-NP	B-protein
and	and	CC	I-NP	O
OM2	OM2	NN	I-NP	B-protein
.	.	.	O	O

Note	Note	NN	B-NP	O
was	be	VBD	B-VP	O
made	make	VBN	I-VP	O
of	of	IN	B-PP	O
markedly	markedly	RB	B-NP	O
elevated	elevate	VBN	I-NP	O
right	right	JJ	I-NP	O
and	and	CC	I-NP	O
left-sided	left-sided	JJ	I-NP	O
filling	filling	NN	I-NP	O
pressures	pressure	NNS	I-NP	O
.	.	.	O	O

No	No	DT	B-NP	O
stents	stent	NNS	I-NP	O
were	be	VBD	B-VP	O
placed	place	VBN	I-VP	O
.	.	.	O	O

We	We	PRP	B-NP	O
continued	continue	VBD	B-VP	O
management	management	NN	B-NP	O
of	of	IN	B-PP	O
her	her	PRP$	B-NP	O
ischemia	ischemia	NN	I-NP	O
with	with	IN	B-PP	O
aspirin	aspirin	NN	B-NP	O
,	,	,	O	O
beta-blocker	beta-blocker	NN	B-NP	O
,	,	,	O	O
Lipitor	Lipitor	NN	B-NP	O
,	,	,	O	O
and	and	CC	O	O
Imdur	Imdur	NNP	B-NP	O
.	.	.	O	O

In	In	IN	B-PP	O
addition	addition	NN	B-NP	O
,	,	,	O	O
we	we	PRP	B-NP	O
started	start	VBD	B-VP	O
an	an	DT	B-NP	O
ACE	ACE	NN	I-NP	O
inhibitor	inhibitor	NN	I-NP	O
,	,	,	O	O
which	which	WDT	B-NP	O
had	have	VBD	B-VP	O
been	be	VBN	I-VP	O
initially	initially	RB	I-VP	O
held	hold	VBN	I-VP	O
due	due	JJ	B-ADJP	O
to	to	TO	B-PP	O
her	her	PRP$	B-NP	O
hypotension	hypotension	NN	I-NP	O
.	.	.	O	O

This	This	DT	B-NP	O
was	be	VBD	B-VP	O
restarted	restart	VBN	I-VP	O
on	on	IN	B-PP	O
10/30/05	10/30/05	CD	B-NP	O
for	for	IN	B-PP	O
afterload	afterload	JJ	B-NP	O
reduction	reduction	NN	I-NP	O
,	,	,	O	O
given	give	VBN	B-PP	O
her	her	PRP$	B-NP	O
severe	severe	JJ	I-NP	O
mitral	mitral	JJ	I-NP	O
regurgitation	regurgitation	NN	I-NP	O
.	.	.	O	O

Over	Over	IN	B-PP	O
the	the	DT	B-NP	O
course	course	NN	I-NP	O
of	of	IN	B-PP	O
her	her	PRP$	B-NP	O
CCU	CCU	NN	I-NP	O
stay	stay	NN	I-NP	O
and	and	CC	O	O
her	her	PRP$	B-NP	O
hospital	hospital	NN	I-NP	O
stay	stay	NN	I-NP	O
on	on	IN	B-PP	O
the	the	DT	B-NP	O
Cardiac	Cardiac	NNP	I-NP	O
Service	Service	NNP	I-NP	O
,	,	,	O	O
she	she	PRP	B-NP	O
continued	continue	VBD	B-VP	O
to	to	TO	I-VP	O
clinically	clinically	RB	I-VP	O
improve	improve	VB	I-VP	O
.	.	.	O	O

We	We	PRP	B-NP	O
felt	feel	VBD	B-VP	O
that	that	IN	B-SBAR	O
her	her	PRP$	B-NP	O
mitral	mitral	JJ	I-NP	O
regurgitation	regurgitation	NN	I-NP	O
was	be	VBD	B-VP	O
likely	likely	RB	B-ADJP	O
dynamic	dynamic	JJ	I-ADJP	O
,	,	,	O	O
related	related	JJ	B-ADJP	O
to	to	TO	B-PP	O
her	her	PRP$	B-NP	O
CHF	CHF	NN	I-NP	B-DNA
flare	flare	NN	I-NP	I-DNA
and	and	CC	I-NP	O
ischemia	ischemia	NN	I-NP	O
.	.	.	O	O

We	We	PRP	B-NP	O
would	would	MD	B-VP	O
recommend	recommend	VB	I-VP	O
outpatient	outpatient	NN	B-NP	O
echo	echo	NN	I-NP	O
for	for	IN	B-PP	O
further	further	JJ	B-NP	O
follow-up	follow-up	NN	I-NP	O
of	of	IN	B-PP	O
her	her	PRP$	B-NP	O
mitral	mitral	JJ	I-NP	O
regurgitation	regurgitation	NN	I-NP	O
.	.	.	O	O

Rhythm	Rhythm	NN	B-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
at	at	IN	B-PP	O
baseline	baseline	NN	B-NP	O
has	have	VBZ	B-VP	O
paroxysmal	paroxysmal	JJ	B-NP	O
atrial	atrial	JJ	I-NP	O
fibrillation	fibrillation	NN	I-NP	O
,	,	,	O	O
on	on	IN	B-PP	O
Coumadin	Coumadin	NN	B-NP	O
.	.	.	O	O

Here	Here	RB	B-ADVP	O
,	,	,	O	O
she	she	PRP	B-NP	O
was	be	VBD	B-VP	O
noted	note	VBN	I-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
in	in	IN	B-PP	O
normal	normal	JJ	B-NP	O
sinus	sinus	NN	I-NP	O
rhythm	rhythm	NN	I-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
Coumadin	Coumadin	NN	I-NP	O
dose	dose	NN	I-NP	O
was	be	VBD	B-VP	O
held	hold	VBN	I-VP	O
for	for	IN	B-PP	O
two	two	CD	B-NP	O
nights	night	NNS	I-NP	O
from	from	IN	B-PP	O
10/30/05	10/30/05	CD	B-NP	O
to	to	TO	B-PP	O
6/5/05	6/5/05	CD	B-NP	O
for	for	IN	B-PP	O
planned	planned	JJ	B-NP	O
TEE	TEE	NN	I-NP	O
echo	echo	NN	I-NP	O
and	and	CC	O	O
a	a	DT	B-NP	O
small	small	JJ	I-NP	O
dose	dose	NN	I-NP	O
of	of	IN	B-PP	O
vitamin	vitamin	NN	B-NP	O
K	K	NN	I-NP	O
was	be	VBD	B-VP	O
given	give	VBN	I-VP	O
.	.	.	O	O

Subsequently	Subsequently	RB	B-ADVP	O
,	,	,	O	O
the	the	DT	B-NP	O
TEE	TEE	NN	I-NP	O
was	be	VBD	B-VP	O
later	later	RB	I-VP	O
canceled	cancel	VBN	I-VP	O
.	.	.	O	O

We	We	PRP	B-NP	O
are	be	VBP	B-VP	O
therefore	therefore	RB	I-VP	O
restarting	restart	VBG	I-VP	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
on	on	IN	B-PP	O
her	her	PRP$	B-NP	O
home	home	NN	I-NP	O
dose	dose	NN	I-NP	O
of	of	IN	B-PP	O
Coumadin	Coumadin	NN	B-NP	O
,	,	,	O	O
but	but	CC	O	O
her	her	PRP$	B-NP	O
INR	INR	NN	I-NP	B-protein
may	may	MD	B-VP	O
rise	rise	VB	I-VP	O
somewhat	somewhat	RB	B-ADVP	O
slowly	slowly	RB	B-ADJP	O
due	due	JJ	I-ADJP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
vitamin	vitamin	NN	I-NP	O
K	K	NN	I-NP	O
.	.	.	O	O

We	We	PRP	B-NP	O
have	have	VBP	B-VP	O
asked	ask	VBN	I-VP	O
her	her	PRP	B-NP	O
to	to	TO	B-VP	O
have	have	VB	I-VP	O
her	her	PRP$	B-NP	O
labs	lab	NNS	I-NP	O
checked	check	VBD	B-VP	O
on	on	IN	B-PP	O
9/13/05	9/13/05	CD	B-NP	O
for	for	IN	B-PP	O
an	an	DT	B-NP	O
INR	INR	NN	I-NP	B-protein
check	check	NN	I-NP	I-protein
.	.	.	O	O

Infectious	Infectious	JJ	B-NP	O
disease	disease	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
noted	note	VBN	I-VP	O
to	to	TO	I-VP	O
have	have	VB	I-VP	O
two	two	CD	B-NP	O
positive	positive	JJ	I-NP	O
cultures	culture	NNS	I-NP	O
for	for	IN	B-PP	O
Coag-negative	Coag-negative	JJ	B-NP	O
staph	staph	NN	I-NP	O
,	,	,	O	O
one	one	CD	B-NP	O
drawn	draw	VBN	B-VP	O
on	on	IN	B-PP	O
2/21/05	2/21/05	CD	B-NP	O
and	and	CC	I-NP	O
one	one	CD	I-NP	O
drawn	draw	VBN	B-VP	O
on	on	IN	B-PP	O
5/29/05	5/29/05	CD	B-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
initially	initially	RB	I-VP	O
started	start	VBN	I-VP	O
on	on	IN	B-PP	O
vancomycin	vancomycin	NN	B-NP	O
on	on	IN	B-PP	O
2/30/05	2/30/05	CD	B-NP	O
and	and	CC	O	O
then	then	RB	B-VP	O
switched	switch	VBN	I-VP	O
to	to	TO	B-PP	O
nafcillin	nafcillin	NN	B-NP	O
based	base	VBN	B-VP	O
on	on	IN	B-PP	O
her	her	PRP$	B-NP	O
sensitivities	sensitivity	NNS	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
plan	plan	NN	I-NP	O
was	be	VBD	B-VP	O
to	to	TO	B-VP	O
obtain	obtain	VB	I-VP	O
a	a	DT	B-NP	O
TEE	TEE	NN	I-NP	O
to	to	TO	B-VP	O
evaluate	evaluate	VB	I-VP	O
her	her	PRP	B-NP	O
for	for	IN	B-PP	O
endocarditis	endocarditis	NN	B-NP	O
.	.	.	O	O

However	However	RB	B-ADVP	O
,	,	,	O	O
on	on	IN	B-PP	O
further	further	JJ	B-NP	O
review	review	NN	I-NP	O
of	of	IN	B-PP	O
the	the	DT	B-NP	O
sensitivity	sensitivity	NN	I-NP	O
,	,	,	O	O
we	we	PRP	B-NP	O
conclude	conclude	VBP	B-VP	O
that	that	IN	B-SBAR	O
two	two	CD	B-NP	O
bottles	bottle	NNS	I-NP	O
represent	represent	VBP	B-VP	O
two	two	CD	B-NP	O
different	different	JJ	I-NP	O
Coag-negative	Coag-negative	JJ	I-NP	B-protein
staph	staph	NN	I-NP	I-protein
species	specie	NNS	I-NP	I-protein
.	.	.	O	O

We	We	PRP	B-NP	O
feel	feel	VBP	B-VP	O
that	that	IN	B-SBAR	O
this	this	DT	B-NP	O
most	most	RBS	B-ADVP	O
likely	likely	RB	I-ADVP	O
represents	represent	VBZ	B-VP	O
contamination	contamination	NN	B-NP	O
rather	rather	RB	B-PP	O
than	than	IN	I-PP	O
true	true	JJ	B-NP	O
bacteremia	bacteremia	NN	I-NP	O
.	.	.	O	O

This	This	DT	B-NP	O
was	be	VBD	B-VP	O
discussed	discuss	VBN	I-VP	O
with	with	IN	B-PP	O
the	the	DT	B-NP	O
ID	ID	NN	I-NP	O
fellow	fellow	NN	I-NP	O
who	who	WP	B-NP	O
agreed	agree	VBD	B-VP	O
with	with	IN	B-PP	O
our	our	PRP$	B-NP	O
assessment	assessment	NN	I-NP	O
.	.	.	O	O

Therefore	Therefore	RB	B-ADVP	O
,	,	,	O	O
the	the	DT	B-NP	O
TEE	TEE	NN	I-NP	O
was	be	VBD	B-VP	O
discontinued	discontinue	VBN	I-VP	O
and	and	CC	O	O
antibiotics	antibiotic	NNS	B-NP	O
were	be	VBD	B-VP	O
also	also	RB	I-VP	O
discontinued	discontinue	VBN	I-VP	O
.	.	.	O	O

We	We	PRP	B-NP	O
asked	ask	VBD	B-VP	O
that	that	IN	B-SBAR	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
have	have	VBP	B-VP	O
surveillance	surveillance	NN	B-NP	O
blood	blood	NN	I-NP	O
cultures	culture	NNS	I-NP	O
checked	check	VBD	B-VP	O
on	on	IN	B-PP	O
9/13/05	9/13/05	CD	B-NP	O
while	while	IN	B-SBAR	O
off	off	IN	B-PP	O
all	all	DT	B-NP	O
antibiotics	antibiotic	NNS	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
also	also	RB	B-ADVP	O
had	have	VBD	B-VP	O
a	a	DT	B-NP	O
positive	positive	JJ	I-NP	O
UA	UA	NNP	I-NP	O
while	while	IN	B-SBAR	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
CCU	CCU	NN	I-NP	B-DNA
and	and	CC	O	O
was	be	VBD	B-VP	O
started	start	VBN	I-VP	O
on	on	IN	B-PP	O
levofloxacin	levofloxacin	NN	B-NP	O
for	for	IN	B-PP	O
a	a	DT	B-NP	O
UTI	UTI	NN	I-NP	B-DNA
.	.	.	O	O

However	However	RB	B-ADVP	O
,	,	,	O	O
her	her	PRP$	B-NP	B-cell_line
urine	urine	NN	I-NP	I-cell_line
cultures	culture	NNS	I-NP	I-cell_line
never	never	RB	B-ADVP	O
grew	grow	VBD	B-VP	O
an	an	DT	B-NP	O
organism	organism	NN	I-NP	O
.	.	.	O	O

So	So	RB	O	O
,	,	,	O	O
this	this	DT	B-NP	O
was	be	VBD	B-VP	O
discontinued	discontinue	VBN	I-VP	O
on	on	IN	B-PP	O
6/16/05	6/16/05	CD	B-NP	O
.	.	.	O	O

Pulmonary	Pulmonary	JJ	B-ADJP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
has	have	VBZ	B-VP	O
a	a	DT	B-NP	O
history	history	NN	I-NP	O
of	of	IN	B-PP	O
COPD	COPD	NN	B-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
continued	continue	VBN	I-VP	O
on	on	IN	B-PP	O
her	her	PRP$	B-NP	O
home	home	NN	I-NP	O
inhalers	inhaler	NNS	I-NP	O
as	as	RB	B-CONJP	O
well	well	RB	I-CONJP	O
as	as	IN	I-CONJP	O
nebulizers	nebulizer	NNS	B-NP	O
as	as	IN	B-PP	O
needed	need	VBN	B-VP	O
.	.	.	O	O

She	She	PRP	B-NP	O
received	receive	VBD	B-VP	O
one	one	CD	B-NP	O
course	course	NN	I-NP	O
of	of	IN	B-PP	O
pulse	pulse	NN	B-NP	O
dose	dose	NN	I-NP	O
steroids	steroid	NNS	I-NP	O
while	while	IN	B-SBAR	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
CCU	CCU	NN	I-NP	O
for	for	IN	B-PP	O
presumed	presume	VBN	B-NP	O
COPD	COPD	NN	I-NP	O
infection	infection	NN	I-NP	O
.	.	.	O	O

This	This	DT	B-NP	O
was	be	VBD	B-VP	O
discontinued	discontinue	VBN	I-VP	O
prior	prior	RB	B-ADVP	O
to	to	TO	B-PP	O
her	her	PRP$	B-NP	O
admission	admission	NN	I-NP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
floor	floor	NN	I-NP	O
.	.	.	O	O

Renal	Renal	JJ	B-ADJP	O
.	.	.	O	O

On	On	IN	B-PP	O
presentation	presentation	NN	B-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
had	have	VBD	B-VP	O
evidence	evidence	NN	B-NP	O
of	of	IN	B-PP	O
acute	acute	JJ	B-NP	O
renal	renal	JJ	I-NP	O
failure	failure	NN	I-NP	O
with	with	IN	B-PP	O
creatinine	creatinine	NN	B-NP	O
elevated	elevate	VBN	B-VP	O
at	at	IN	B-PP	O
2.3	2.3	CD	B-NP	O
.	.	.	O	O

However	However	RB	B-ADVP	O
,	,	,	O	O
this	this	DT	B-NP	O
improved	improve	VBD	B-VP	O
with	with	IN	B-PP	O
diuresis	diuresis	NN	B-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
also	also	RB	B-ADVP	O
had	have	VBD	B-VP	O
an	an	DT	B-NP	O
MRI	MRI	NN	I-NP	B-protein
of	of	IN	B-PP	O
the	the	DT	B-NP	O
kidneys	kidney	NNS	I-NP	O
to	to	TO	B-VP	O
evaluate	evaluate	VB	I-VP	O
for	for	IN	B-PP	O
renal	renal	JJ	B-NP	O
artery	artery	NN	I-NP	O
stenosis	stenosis	NN	I-NP	O
on	on	IN	B-PP	O
6/16/05	6/16/05	CD	B-NP	O
.	.	.	O	O

This	This	DT	B-NP	O
showed	show	VBD	B-VP	O
severe	severe	JJ	B-NP	O
diffuse	diffuse	JJ	I-NP	O
atherosclerotic	atherosclerotic	JJ	I-NP	O
disease	disease	NN	I-NP	O
of	of	IN	B-PP	O
the	the	DT	B-NP	O
abdominal	abdominal	JJ	I-NP	O
aorta	aorta	NN	I-NP	O
,	,	,	O	O
but	but	CC	O	O
no	no	DT	B-NP	O
renal	renal	JJ	I-NP	O
artery	artery	NN	I-NP	O
stenosis	stenosis	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
radiologist	radiologist	NN	I-NP	O
recommends	recommend	VBZ	B-VP	O
a	a	DT	B-NP	O
CT	CT	NN	I-NP	O
angiogram	angiogram	NN	I-NP	O
for	for	IN	B-PP	O
further	further	JJ	B-NP	O
work	work	NN	I-NP	O
if	if	IN	B-SBAR	O
clinically	clinically	RB	B-ADVP	O
indicated	indicate	VBN	B-VP	O
as	as	IN	B-PP	O
an	an	DT	B-NP	O
outpatient	outpatient	NN	I-NP	O
.	.	.	O	O

Endocrine	Endocrine	JJ	B-ADJP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
has	have	VBZ	B-VP	O
a	a	DT	B-NP	O
history	history	NN	I-NP	O
of	of	IN	B-PP	O
diabetes	diabetes	NN	B-NP	O
and	and	CC	O	O
is	be	VBZ	B-VP	O
on	on	IN	B-PP	O
Lantus	Lantus	NNP	B-NP	O
and	and	CC	O	O
metformin	metformin	NN	B-NP	O
at	at	IN	B-PP	O
home	home	NN	B-NP	O
.	.	.	O	O

Here	Here	RB	B-ADVP	O
,	,	,	O	O
we	we	PRP	B-NP	O
held	hold	VBD	B-VP	O
her	her	PRP$	B-NP	O
metformin	metformin	NN	I-NP	O
dose	dose	NN	I-NP	O
and	and	CC	O	O
treated	treat	VBN	B-VP	O
her	her	PRP	B-NP	O
instead	instead	RB	B-ADVP	O
with	with	IN	B-PP	O
insulin	insulin	NN	B-NP	B-protein
sliding	slide	VBG	B-VP	O
scale	scale	NN	B-NP	O
and	and	CC	I-NP	O
Lantus	Lantus	NN	I-NP	O
.	.	.	O	O

We	We	PRP	B-NP	O
have	have	VBP	B-VP	O
asked	ask	VBN	I-VP	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
to	to	TO	B-VP	O
restart	restart	VB	I-VP	O
her	her	PRP$	B-NP	O
metformin	metformin	NN	I-NP	O
upon	upon	IN	B-PP	O
discharge	discharge	NN	B-NP	O
.	.	.	O	O

FEN	FEN	NN	B-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
's	's	POS	B-NP	O
goal	goal	NN	I-NP	O
in	in	IN	B-PP	O
's	's	POS	B-NP	O
and	and	CC	O	O
out	out	RP	B-PRT	O
's	's	POS	B-NP	O
should	should	MD	B-VP	O
be	be	VB	I-VP	O
even	even	RB	B-ADVP	O
to	to	TO	B-PP	O
-500	-500	CD	B-NP	O
ml	ml	NN	I-NP	O
per	per	IN	B-PP	O
day	day	NN	B-NP	O
.	.	.	O	O

We	We	PRP	B-NP	O
increased	increase	VBD	B-VP	O
her	her	PRP$	B-NP	O
home	home	NN	I-NP	O
Lasix	Lasix	NN	I-NP	O
dose	dose	NN	I-NP	O
from	from	IN	B-PP	O
80	80	CD	B-NP	O
mg	mg	NN	I-NP	O
daily	daily	JJ	B-ADJP	O
to	to	TO	B-PP	O
80	80	CD	B-NP	O
mg	mg	NN	I-NP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
morning	morning	NN	I-NP	O
and	and	CC	I-NP	O
40	40	CD	I-NP	O
mg	mg	NN	I-NP	O
at	at	IN	B-PP	O
night	night	NN	B-NP	O
.	.	.	O	O

These	These	DT	B-NP	O
doses	dose	NNS	I-NP	O
should	should	MD	B-VP	O
be	be	VB	I-VP	O
subsequently	subsequently	RB	I-VP	O
adjusted	adjust	VBN	I-VP	O
to	to	TO	I-VP	O
maintain	maintain	VB	I-VP	O
her	her	PRP$	B-NP	O
volume	volume	NN	I-NP	O
status	status	NN	I-NP	O
as	as	IN	B-PP	O
an	an	DT	B-NP	O
outpatient	outpatient	NN	I-NP	O
.	.	.	O	O

Code	Code	NNP	B-NP	O
.	.	.	O	O

Status	Status	NNP	B-NP	O
is	be	VBZ	B-VP	O
full	full	JJ	B-NP	O
code	code	NN	I-NP	O
.	.	.	O	O

DISPOSITION	DISPOSITION	NN	B-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
discharged	discharge	VBN	I-VP	O
home	home	NN	B-ADVP	O
on	on	IN	B-PP	O
1/7/05	1/7/05	CD	B-NP	O
with	with	IN	B-PP	O
VNA	VNA	NNP	B-NP	O
Services	Service	NNPS	I-NP	O
.	.	.	O	O

VNA	VNA	NN	B-NP	B-protein
should	should	MD	B-VP	O
assist	assist	VB	I-VP	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
with	with	IN	B-PP	O
her	her	PRP$	B-NP	O
medications	medication	NNS	I-NP	O
as	as	RB	B-CONJP	O
well	well	RB	I-CONJP	O
as	as	IN	I-CONJP	O
volume	volume	NN	B-NP	O
status	status	NN	I-NP	O
checks	check	NNS	I-NP	O
,	,	,	O	O
daily	daily	JJ	B-NP	O
weights	weight	NNS	I-NP	O
,	,	,	O	O
and	and	CC	O	O
lung	lung	NN	B-NP	B-cell_type
exams	exam	NNS	I-NP	I-cell_type
.	.	.	O	O

She	She	PRP	B-NP	O
has	have	VBZ	B-VP	O
a	a	DT	B-NP	O
follow-up	follow-up	JJ	I-NP	O
appointment	appointment	NN	I-NP	O
already	already	RB	B-VP	O
scheduled	schedule	VBN	I-VP	O
with	with	IN	B-PP	O
her	her	PRP$	B-NP	O
primary	primary	JJ	I-NP	O
care	care	NN	I-NP	O
doctor	doctor	NN	I-NP	O
,	,	,	O	O
Dr.	Dr.	NNP	B-NP	O
Wagenheim	Wagenheim	NNP	I-NP	O
,	,	,	O	O
on	on	IN	B-PP	O
9/29/05	9/29/05	CD	B-NP	O
at	at	IN	B-PP	O
2	2	CD	B-NP	O
:	:	:	O	O
30	30	CD	B-NP	O
p.m.	p.m.	RB	I-NP	O
.	.	.	O	O

In	In	IN	B-PP	O
addition	addition	NN	B-NP	O
,	,	,	O	O
Dr.	Dr.	NNP	B-NP	O
Rayome	Rayome	NNP	I-NP	O
of	of	IN	B-PP	O
the	the	DT	B-NP	O
Cardiology	Cardiology	NNP	I-NP	O
Service	Service	NNP	I-NP	O
will	will	MD	B-VP	O
see	see	VB	I-VP	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
as	as	IN	B-PP	O
an	an	DT	B-NP	O
outpatient	outpatient	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
exact	exact	JJ	I-NP	O
appointment	appointment	NN	I-NP	O
time	time	NN	I-NP	O
and	and	CC	I-NP	O
date	date	NN	I-NP	O
are	be	VBP	B-VP	O
pending	pende	VBG	I-VP	O
at	at	IN	B-PP	O
the	the	DT	B-NP	O
time	time	NN	I-NP	O
of	of	IN	B-PP	O
this	this	DT	B-NP	O
dictation	dictation	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
office	office	NN	I-NP	O
has	have	VBZ	B-VP	O
indicated	indicate	VBN	I-VP	O
that	that	IN	B-SBAR	O
they	they	PRP	B-NP	O
will	will	MD	B-VP	O
call	call	VB	I-VP	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
for	for	IN	B-PP	O
a	a	DT	B-NP	O
specific	specific	JJ	I-NP	O
appointment	appointment	NN	I-NP	O
time	time	NN	I-NP	O
.	.	.	O	O

MEDICATIONS	MEDICATIONS	NNS	B-NP	O
ON	ON	NN	I-NP	O
DISCHARGE	DISCHARGE	NN	I-NP	O
:	:	:	O	O
1	1	LS	B-LST	O
.	.	.	O	O

Aspirin	Aspirin	NN	B-NP	O
325	325	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	RB	B-ADVP	O
daily	daily	RB	I-ADVP	O
.	.	.	O	O

2	2	LS	B-LST	O
.	.	.	O	O

Ferrous	Ferrous	JJ	B-NP	B-protein
sulfate	sulfate	NN	I-NP	I-protein
325	325	CD	I-NP	I-protein
mg	mg	NN	I-NP	I-protein
p.o.	p.o.	NN	I-NP	I-protein
t.i.d.	t.i.d.	NN	I-NP	I-protein
3	3	CD	I-NP	I-protein
.	.	.	O	O

Lasix	Lasix	NN	B-NP	O
80	80	CD	I-NP	O
mg	mg	NN	I-NP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
morning	morning	NN	I-NP	O
and	and	CC	I-NP	O
40	40	CD	I-NP	O
mg	mg	NN	I-NP	O
at	at	IN	B-PP	O
night	night	NN	B-NP	O
.	.	.	O	O

4	4	LS	B-LST	O
.	.	.	O	O

Magnesium	Magnesium	NN	B-NP	O
oxide	oxide	NN	I-NP	O
420	420	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	RB	B-ADVP	O
daily	daily	RB	I-ADVP	O
.	.	.	O	O

5	5	LS	B-LST	O
.	.	.	O	O

Zoloft	Zoloft	NNP	B-NP	O
200	200	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	RB	B-ADVP	O
daily	daily	RB	I-ADVP	O
.	.	.	O	O

6	6	CD	B-NP	O
.	.	.	O	O

Imdur	Imdur	IN	B-PP	O
30	30	CD	B-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	RB	B-ADVP	O
daily	daily	RB	I-ADVP	O
.	.	.	O	O

7	7	CD	B-NP	O
.	.	.	O	O

Loratadine	Loratadine	NN	B-NP	O
10	10	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	RB	B-ADVP	O
daily	daily	RB	I-ADVP	O
.	.	.	O	O

8	8	CD	B-NP	O
.	.	.	O	O

Flovent	Flovent	NN	B-NP	B-protein
440	440	CD	I-NP	I-protein
mcg	mcg	NN	I-NP	I-protein
inhaled	inhale	VBD	B-VP	I-protein
b.i.d.	b.i.d.	NN	B-NP	I-protein
9	9	CD	I-NP	I-protein
.	.	.	O	O

Lipitor	Lipitor	NN	B-NP	O
80	80	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	RB	B-ADVP	O
daily	daily	RB	I-ADVP	O
.	.	.	O	O

10	10	CD	B-NP	O
.	.	.	O	O

Wellbutrin	Wellbutrin	NN	B-NP	O
100	100	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
b.i.d.	b.i.d.	NN	I-NP	O
11	11	CD	I-NP	O
.	.	.	O	O

Salmeterol	Salmeterol	NN	B-NP	O
one	one	CD	B-NP	O
puff	puff	NN	I-NP	O
twice	twice	RB	B-NP	O
a	a	DT	I-NP	O
day	day	NN	I-NP	O
.	.	.	O	O

12	12	CD	B-NP	O
.	.	.	O	O

Nexium	Nexium	NN	B-NP	O
40	40	CD	I-NP	O
mg	mg	NN	I-NP	O
a	a	DT	B-NP	O
day	day	NN	I-NP	O
.	.	.	O	O

13	13	CD	B-NP	O
.	.	.	O	O

Lantus	Lantus	NNP	B-NP	O
10	10	CD	I-NP	O
units	unit	NNS	I-NP	O
every	every	DT	B-NP	O
evening	evening	NN	I-NP	O
.	.	.	O	O

14	14	CD	B-NP	O
.	.	.	O	O

Lisinopril	Lisinopril	NNP	B-NP	O
5	5	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	RB	B-ADVP	O
daily	daily	RB	I-ADVP	O
.	.	.	O	O

15	15	CD	B-NP	O
.	.	.	O	O

Lasix	Lasix	NNP	B-NP	O
40	40	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
q.p.m.	q.p.m.	NN	I-NP	O
16	16	CD	I-NP	O
.	.	.	O	O

Metoprolol	Metoprolol	NN	B-NP	O
150	150	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	RB	B-ADVP	O
daily	daily	RB	I-ADVP	O
.	.	.	O	O

17	17	CD	B-NP	O
.	.	.	O	O

Metformin	Metformin	NN	B-NP	O
1000	1000	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	B-NP	O
b.i.d.	b.i.d.	FW	I-NP	O
18	18	CD	I-NP	O
.	.	.	O	O

Coumadin	Coumadin	NN	B-NP	O
2.5	2.5	CD	I-NP	O
p.o.	p.o.	NN	I-NP	O
q.p.m.	q.p.m.	NN	I-NP	O
19	19	CD	I-NP	O
.	.	.	O	O

Nitroglycerin	Nitroglycerin	NN	B-NP	O
one	one	CD	I-NP	O
tablet	tablet	NN	I-NP	O
sublingual	sublingual	JJ	I-NP	O
q.	q.	NN	I-NP	O
5	5	CD	B-NP	O
minutes	minute	NNS	I-NP	O
x3	x3	CD	B-NP	O
doses	dose	NNS	I-NP	O
p.r.n.	p.r.n.	VBP	B-VP	O
chest	chest	NN	B-NP	O
pain	pain	NN	I-NP	O
.	.	.	O	O

20	20	CD	B-NP	O
.	.	.	O	O

Potassium	Potassium	NN	B-NP	O
chloride	chloride	NN	I-NP	O
slow	slow	JJ	I-NP	O
release	release	NN	I-NP	O
20	20	CD	I-NP	O
mEq	mEq	NN	I-NP	O
.	.	.	O	O

p.o.	p.o.	RB	B-ADVP	O
daily	daily	RB	I-ADVP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
's	's	POS	B-NP	O
Lantus	Lantus	NNP	I-NP	O
dose	dose	NN	I-NP	O
should	should	MD	B-VP	O
be	be	VB	I-VP	O
adjusted	adjust	VBN	I-VP	O
according	accord	VBG	B-PP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
blood	blood	NN	I-NP	O
glucose	glucose	NN	I-NP	O
levels	level	NNS	I-NP	O
at	at	IN	B-PP	O
home	home	NN	B-NP	O
.	.	.	O	O

eScription	eScription	NN	B-NP	O
document	document	NN	I-NP	O
:	:	:	O	O
2-4381154	2-4381154	CD	B-NP	O
CS	CS	NN	I-NP	O
CC	CC	NN	I-NP	O
:	:	:	O	O
Mel	Mel	NNP	B-NP	O
Carballo	Carballo	NNP	I-NP	O
M.D.	M.D.	NNP	I-NP	O
CVD	CVD	NNP	I-NP	O
MZ3	MZ3	NNP	I-NP	O
,	,	,	O	O
Angels	Angels	NNP	B-NP	O
-	-	HYPH	O	O
Region	Region	NNP	B-NP	O
Health	Health	NNP	I-NP	O
Care	Care	NNP	I-NP	O
Za	Za	NNP	I-NP	O
Lina	Lina	NNP	I-NP	O
CC	CC	NNP	I-NP	O
:	:	:	O	O
Jospeh	Jospeh	NNP	B-NP	O
Yamamoto	Yamamoto	NNP	I-NP	O
MD	MD	NNP	I-NP	O
More	More	NNP	I-NP	O
Shing	Shing	NNP	I-NP	O
E	E	NNP	I-NP	O
Bock	Bock	NNP	I-NP	O
Dictated	Dictated	NNP	I-NP	O
By	By	NNP	I-NP	O
:	:	:	O	O
SANDOVAR	SANDOVAR	NNP	B-NP	O
,	,	,	O	O
FRED	FRED	NNP	B-NP	O
Attending	Attending	NNP	I-NP	O
:	:	:	O	O
STIFEL	STIFEL	NN	B-NP	O
,	,	,	O	O
IRWIN	IRWIN	NNP	B-NP	O
Dictation	Dictation	NNP	I-NP	O
ID	ID	NNP	I-NP	O
9797823	9797823	CD	I-NP	O
D	D	NNP	I-NP	O
:	:	:	O	O
1/7/05	1/7/05	CD	B-NP	O
T	T	NN	I-NP	O
:	:	:	O	O
10/13/05	10/13/05	CD	B-NP	O

